Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3

Donna Pauler Ankerst, Jack Groskopf, John R. Day, Amy Blase, Harry Rittenhouse, Bradley H Pollock, Cathy Tangen, Dipen Parekh, Robin J. Leach, Ian Thompson

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Purpose: The online Prostate Cancer Prevention Trial risk calculator combines prostate specific antigen, digital rectal examination, family and biopsy history, age and race to determine the risk of prostate cancer. In this report we incorporate the biomarker prostate cancer gene 3 into the Prostate Cancer Prevention Trial risk calculator. Materials and Methods: Methodology was developed to incorporate new markers for prostate cancer into the Prostate Cancer Prevention Trial risk calculator based on likelihood ratios calculated from separate case control or cohort studies. The methodology was applied to incorporate the marker prostate cancer gene 3 into the risk calculator based on a cohort of 521 men who underwent prostate biopsy with measurements of urinary prostate cancer gene 3, serum prostate specific antigen, digital rectal examination and biopsy history. External validation of the updated risk calculator was performed on a cohort of 443 European patients, and compared to Prostate Cancer Prevention Trial risks, prostate specific antigen and prostate cancer gene 3 by area underneath the receiver operating characteristic curve, sensitivity and specificity. Results: The AUC of posterior risks (AUC 0.696, 95% CI 0.641-0.750) was higher than that of prostate specific antigen (AUC 0.607, 95% CI 0.546-0.668, p = 0.001) and Prostate Cancer Prevention Trial risks (AUC 0.653, 95% CI 0.593-0.714, p <0.05). Although it was higher it was not statistically significantly different from that of prostate cancer gene 3 (AUC 0.665, 95% CI 0.610-0.721, p >0.05). Sensitivities of posterior risks were higher than those of prostate cancer gene 3, prostate specific antigen and Prostate Cancer Prevention Trial risks. Conclusions: New markers for prostate cancer can be incorporated into the Prostate Cancer Prevention Trial risk calculator by a novel approach. Incorporation of prostate cancer gene 3 improved the diagnostic accuracy of the Prostate Cancer Prevention Trial risk calculator.

Original languageEnglish (US)
Pages (from-to)1303-1308
Number of pages6
JournalJournal of Urology
Volume180
Issue number4
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Neoplasm Genes
Prostatic Neoplasms
Prostate-Specific Antigen
Area Under Curve
Digital Rectal Examination
Biopsy
History

Keywords

  • biological markers
  • human
  • likelihood functions
  • prostate cancer antigen 3
  • prostatic neoplasms
  • risk assessment

ASJC Scopus subject areas

  • Urology

Cite this

Ankerst, D. P., Groskopf, J., Day, J. R., Blase, A., Rittenhouse, H., Pollock, B. H., ... Thompson, I. (2008). Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3. Journal of Urology, 180(4), 1303-1308. https://doi.org/10.1016/j.juro.2008.06.038

Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3. / Ankerst, Donna Pauler; Groskopf, Jack; Day, John R.; Blase, Amy; Rittenhouse, Harry; Pollock, Bradley H; Tangen, Cathy; Parekh, Dipen; Leach, Robin J.; Thompson, Ian.

In: Journal of Urology, Vol. 180, No. 4, 10.2008, p. 1303-1308.

Research output: Contribution to journalArticle

Ankerst, DP, Groskopf, J, Day, JR, Blase, A, Rittenhouse, H, Pollock, BH, Tangen, C, Parekh, D, Leach, RJ & Thompson, I 2008, 'Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3', Journal of Urology, vol. 180, no. 4, pp. 1303-1308. https://doi.org/10.1016/j.juro.2008.06.038
Ankerst, Donna Pauler ; Groskopf, Jack ; Day, John R. ; Blase, Amy ; Rittenhouse, Harry ; Pollock, Bradley H ; Tangen, Cathy ; Parekh, Dipen ; Leach, Robin J. ; Thompson, Ian. / Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3. In: Journal of Urology. 2008 ; Vol. 180, No. 4. pp. 1303-1308.
@article{17602b096ea249a086050086690f25d3,
title = "Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3",
abstract = "Purpose: The online Prostate Cancer Prevention Trial risk calculator combines prostate specific antigen, digital rectal examination, family and biopsy history, age and race to determine the risk of prostate cancer. In this report we incorporate the biomarker prostate cancer gene 3 into the Prostate Cancer Prevention Trial risk calculator. Materials and Methods: Methodology was developed to incorporate new markers for prostate cancer into the Prostate Cancer Prevention Trial risk calculator based on likelihood ratios calculated from separate case control or cohort studies. The methodology was applied to incorporate the marker prostate cancer gene 3 into the risk calculator based on a cohort of 521 men who underwent prostate biopsy with measurements of urinary prostate cancer gene 3, serum prostate specific antigen, digital rectal examination and biopsy history. External validation of the updated risk calculator was performed on a cohort of 443 European patients, and compared to Prostate Cancer Prevention Trial risks, prostate specific antigen and prostate cancer gene 3 by area underneath the receiver operating characteristic curve, sensitivity and specificity. Results: The AUC of posterior risks (AUC 0.696, 95{\%} CI 0.641-0.750) was higher than that of prostate specific antigen (AUC 0.607, 95{\%} CI 0.546-0.668, p = 0.001) and Prostate Cancer Prevention Trial risks (AUC 0.653, 95{\%} CI 0.593-0.714, p <0.05). Although it was higher it was not statistically significantly different from that of prostate cancer gene 3 (AUC 0.665, 95{\%} CI 0.610-0.721, p >0.05). Sensitivities of posterior risks were higher than those of prostate cancer gene 3, prostate specific antigen and Prostate Cancer Prevention Trial risks. Conclusions: New markers for prostate cancer can be incorporated into the Prostate Cancer Prevention Trial risk calculator by a novel approach. Incorporation of prostate cancer gene 3 improved the diagnostic accuracy of the Prostate Cancer Prevention Trial risk calculator.",
keywords = "biological markers, human, likelihood functions, prostate cancer antigen 3, prostatic neoplasms, risk assessment",
author = "Ankerst, {Donna Pauler} and Jack Groskopf and Day, {John R.} and Amy Blase and Harry Rittenhouse and Pollock, {Bradley H} and Cathy Tangen and Dipen Parekh and Leach, {Robin J.} and Ian Thompson",
year = "2008",
month = "10",
doi = "10.1016/j.juro.2008.06.038",
language = "English (US)",
volume = "180",
pages = "1303--1308",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3

AU - Ankerst, Donna Pauler

AU - Groskopf, Jack

AU - Day, John R.

AU - Blase, Amy

AU - Rittenhouse, Harry

AU - Pollock, Bradley H

AU - Tangen, Cathy

AU - Parekh, Dipen

AU - Leach, Robin J.

AU - Thompson, Ian

PY - 2008/10

Y1 - 2008/10

N2 - Purpose: The online Prostate Cancer Prevention Trial risk calculator combines prostate specific antigen, digital rectal examination, family and biopsy history, age and race to determine the risk of prostate cancer. In this report we incorporate the biomarker prostate cancer gene 3 into the Prostate Cancer Prevention Trial risk calculator. Materials and Methods: Methodology was developed to incorporate new markers for prostate cancer into the Prostate Cancer Prevention Trial risk calculator based on likelihood ratios calculated from separate case control or cohort studies. The methodology was applied to incorporate the marker prostate cancer gene 3 into the risk calculator based on a cohort of 521 men who underwent prostate biopsy with measurements of urinary prostate cancer gene 3, serum prostate specific antigen, digital rectal examination and biopsy history. External validation of the updated risk calculator was performed on a cohort of 443 European patients, and compared to Prostate Cancer Prevention Trial risks, prostate specific antigen and prostate cancer gene 3 by area underneath the receiver operating characteristic curve, sensitivity and specificity. Results: The AUC of posterior risks (AUC 0.696, 95% CI 0.641-0.750) was higher than that of prostate specific antigen (AUC 0.607, 95% CI 0.546-0.668, p = 0.001) and Prostate Cancer Prevention Trial risks (AUC 0.653, 95% CI 0.593-0.714, p <0.05). Although it was higher it was not statistically significantly different from that of prostate cancer gene 3 (AUC 0.665, 95% CI 0.610-0.721, p >0.05). Sensitivities of posterior risks were higher than those of prostate cancer gene 3, prostate specific antigen and Prostate Cancer Prevention Trial risks. Conclusions: New markers for prostate cancer can be incorporated into the Prostate Cancer Prevention Trial risk calculator by a novel approach. Incorporation of prostate cancer gene 3 improved the diagnostic accuracy of the Prostate Cancer Prevention Trial risk calculator.

AB - Purpose: The online Prostate Cancer Prevention Trial risk calculator combines prostate specific antigen, digital rectal examination, family and biopsy history, age and race to determine the risk of prostate cancer. In this report we incorporate the biomarker prostate cancer gene 3 into the Prostate Cancer Prevention Trial risk calculator. Materials and Methods: Methodology was developed to incorporate new markers for prostate cancer into the Prostate Cancer Prevention Trial risk calculator based on likelihood ratios calculated from separate case control or cohort studies. The methodology was applied to incorporate the marker prostate cancer gene 3 into the risk calculator based on a cohort of 521 men who underwent prostate biopsy with measurements of urinary prostate cancer gene 3, serum prostate specific antigen, digital rectal examination and biopsy history. External validation of the updated risk calculator was performed on a cohort of 443 European patients, and compared to Prostate Cancer Prevention Trial risks, prostate specific antigen and prostate cancer gene 3 by area underneath the receiver operating characteristic curve, sensitivity and specificity. Results: The AUC of posterior risks (AUC 0.696, 95% CI 0.641-0.750) was higher than that of prostate specific antigen (AUC 0.607, 95% CI 0.546-0.668, p = 0.001) and Prostate Cancer Prevention Trial risks (AUC 0.653, 95% CI 0.593-0.714, p <0.05). Although it was higher it was not statistically significantly different from that of prostate cancer gene 3 (AUC 0.665, 95% CI 0.610-0.721, p >0.05). Sensitivities of posterior risks were higher than those of prostate cancer gene 3, prostate specific antigen and Prostate Cancer Prevention Trial risks. Conclusions: New markers for prostate cancer can be incorporated into the Prostate Cancer Prevention Trial risk calculator by a novel approach. Incorporation of prostate cancer gene 3 improved the diagnostic accuracy of the Prostate Cancer Prevention Trial risk calculator.

KW - biological markers

KW - human

KW - likelihood functions

KW - prostate cancer antigen 3

KW - prostatic neoplasms

KW - risk assessment

UR - http://www.scopus.com/inward/record.url?scp=50949128308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949128308&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.06.038

DO - 10.1016/j.juro.2008.06.038

M3 - Article

C2 - 18707724

AN - SCOPUS:50949128308

VL - 180

SP - 1303

EP - 1308

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -